Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Cabozantinibe-S-Malato no tratamento de pacientes mais jovens com sarcomas recorrentes, refratários ou diagnosticados recentemente, tumor de Wilms ou outros tumores raros

10 de novembro de 2026 atualizado por: National Cancer Institute (NCI)

Ensaio de Fase 2 de XL184 (Cabozantinibe), um Inibidor Oral de Pequena Molécula de Múltiplas Quinases, em Crianças e Jovens Adultos com Sarcomas Refratários, Tumor de Wilms e Outros Tumores Raros

This phase II trial studies how well cabozantinib-s-malate works in treating younger patients with sarcomas, Wilms tumor, or other rare tumors that have come back, do not respond to therapy, or are newly diagnosed. Cabozantinib-s-malate may stop the growth of tumor cells by blocking some of the enzymes needed for tumor growth and tumor blood vessel growth.

Visão geral do estudo

Status

Ativo, não recrutando

Condições

Intervenção / Tratamento

Descrição detalhada

PRIMARY OBJECTIVES:

I. To determine the objective response rate (complete response + partial response) of cabozantinib-s-malate (XL184) in children and young adults with Ewing sarcoma, rhabdomyosarcoma, non-rhabdomyosarcoma soft tissue sarcoma, and Wilms tumor.

II. To estimate whether XL184 therapy either improves the disease control rate at 4 months in patients with recurrent measurable osteosarcoma as compared to a historical Childrens Oncology Group (COG) experience or produces an objective response rate.

SECONDARY OBJECTIVES:

I. To further define XL184 related toxicities in pediatric, adolescent and young adult patients.

II. To further define XL184 pharmacokinetics in the pediatric and adolescent patients.

III. To estimate 1-year time to progression, progression free survival (PFS) and overall survival for each stratum, and if feasible to compare to historical controls.

EXPLORATORY OBJECTIVES:

I. To assess the effect of XL184 on patients' immune cell subsets. II. To obtain tumor tissue (snap frozen, formalin-fixed and paraffin-embedded [FFPE] blocks, or unstained slides) from diagnosis, recurrence, or both, for possible future studies.

OUTLINE:

Patients receive cabozantinib-s-malate orally (PO) on a continuous dosing schedule using a dosing nomogram on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up at 30 days, every 6 months for 1 year and then annually for up to 5 years.

Tipo de estudo

Intervencional

Inscrição (Real)

109

Estágio

  • Fase 2

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Locais de estudo

    • Alabama
      • Birmingham, Alabama, Estados Unidos, 35233
        • Children's Hospital of Alabama
    • Alaska
      • Anchorage, Alaska, Estados Unidos, 99508
        • Providence Alaska Medical Center
    • Arkansas
      • Little Rock, Arkansas, Estados Unidos, 72202-3591
        • Arkansas Children's Hospital
    • California
      • Anaheim, California, Estados Unidos, 92806
        • Kaiser Permanente-Anaheim
      • Bellflower, California, Estados Unidos, 90706
        • Kaiser Permanente-Bellflower
      • Downey, California, Estados Unidos, 90242
        • Kaiser Permanente Downey Medical Center
      • Fontana, California, Estados Unidos, 92335
        • Kaiser Permanente-Fontana
      • Loma Linda, California, Estados Unidos, 92354
        • Loma Linda University Medical Center
      • Los Angeles, California, Estados Unidos, 90027
        • Children's Hospital Los Angeles
      • Los Angeles, California, Estados Unidos, 90027
        • Kaiser Permanente Los Angeles Medical Center
      • Madera, California, Estados Unidos, 93636
        • Valley Children's Hospital
      • Oakland, California, Estados Unidos, 94609
        • UCSF Benioff Children's Hospital Oakland
      • Oakland, California, Estados Unidos, 94611
        • Kaiser Permanente-Oakland
      • Orange, California, Estados Unidos, 92868
        • Children's Hospital of Orange County
      • Palo Alto, California, Estados Unidos, 94304
        • Lucile Packard Children's Hospital Stanford University
      • Sacramento, California, Estados Unidos, 95817
        • University of California Davis Comprehensive Cancer Center
      • San Diego, California, Estados Unidos, 92123
        • Rady Children's Hospital - San Diego
      • San Diego, California, Estados Unidos, 92108
        • Kaiser Permanente-Rio San Diego
      • San Francisco, California, Estados Unidos, 94158
        • UCSF Medical Center-Mission Bay
    • Colorado
      • Aurora, Colorado, Estados Unidos, 80045
        • Children's Hospital Colorado
      • Denver, Colorado, Estados Unidos, 80218
        • Rocky Mountain Hospital for Children-Presbyterian Saint Luke's Medical Center
    • Connecticut
      • Hartford, Connecticut, Estados Unidos, 06106
        • Connecticut Children's Medical Center
      • New Haven, Connecticut, Estados Unidos, 06520
        • Yale University
    • Delaware
      • Wilmington, Delaware, Estados Unidos, 19803
        • Alfred I duPont Hospital for Children
    • District of Columbia
      • Washington D.C., District of Columbia, Estados Unidos, 20010
        • Children's National Medical Center
      • Washington D.C., District of Columbia, Estados Unidos, 20002
        • Kaiser Permanente-Capitol Hill Medical Center
      • Washington D.C., District of Columbia, Estados Unidos, 20007
        • MedStar Georgetown University Hospital
    • Florida
      • Fort Myers, Florida, Estados Unidos, 33908
        • Golisano Children's Hospital of Southwest Florida
      • Gainesville, Florida, Estados Unidos, 32610
        • UF Health Cancer Institute - Gainesville
      • Jacksonville, Florida, Estados Unidos, 32207
        • Nemours Children's Clinic-Jacksonville
      • Miami, Florida, Estados Unidos, 33155
        • Nicklaus Children's Hospital
      • Miami, Florida, Estados Unidos, 33136
        • University of Miami Miller School of Medicine-Sylvester Cancer Center
      • Orlando, Florida, Estados Unidos, 32827
        • Nemours Children's Hospital
      • Orlando, Florida, Estados Unidos, 32803
        • AdventHealth Orlando
      • Orlando, Florida, Estados Unidos, 32806
        • Arnold Palmer Hospital for Children
      • Pensacola, Florida, Estados Unidos, 32504
        • Nemours Children's Clinic - Pensacola
      • St. Petersburg, Florida, Estados Unidos, 33701
        • Johns Hopkins All Children's Hospital
    • Georgia
      • Atlanta, Georgia, Estados Unidos, 30329
        • Children's Healthcare of Atlanta - Arthur M Blank Hospital
    • Hawaii
      • Honolulu, Hawaii, Estados Unidos, 96813
        • Straub Clinic and Hospital
      • Honolulu, Hawaii, Estados Unidos, 96826
        • Kapiolani Medical Center for Women and Children
      • Honolulu, Hawaii, Estados Unidos, 96819
        • Kaiser Permanente Moanalua Medical Center
    • Idaho
      • Boise, Idaho, Estados Unidos, 83712
        • Saint Luke's Cancer Institute - Boise
    • Illinois
      • Chicago, Illinois, Estados Unidos, 60637
        • University of Chicago Comprehensive Cancer Center
      • Chicago, Illinois, Estados Unidos, 60612
        • University of Illinois
      • Chicago, Illinois, Estados Unidos, 60611
        • Lurie Children's Hospital-Chicago
      • Danville, Illinois, Estados Unidos, 61832
        • Carle at The Riverfront
      • Effingham, Illinois, Estados Unidos, 62401
        • Carle Physician Group-Effingham
      • Mattoon, Illinois, Estados Unidos, 61938
        • Carle Physician Group-Mattoon/Charleston
      • Peoria, Illinois, Estados Unidos, 61637
        • OSF Children's Hospital of Illinois
      • Urbana, Illinois, Estados Unidos, 61801
        • Carle Cancer Center
      • Urbana, Illinois, Estados Unidos, 61801
        • The Carle Foundation Hospital
    • Indiana
      • Indianapolis, Indiana, Estados Unidos, 46202
        • Riley Hospital for Children
      • Indianapolis, Indiana, Estados Unidos, 46260
        • Ascension Saint Vincent Indianapolis Hospital
    • Iowa
      • Des Moines, Iowa, Estados Unidos, 50309
        • Iowa Methodist Medical Center
      • Des Moines, Iowa, Estados Unidos, 50309
        • Blank Children's Hospital
      • Des Moines, Iowa, Estados Unidos, 50316
        • Iowa Lutheran Hospital
      • Iowa City, Iowa, Estados Unidos, 52242
        • University of Iowa/Holden Comprehensive Cancer Center
    • Kentucky
      • Lexington, Kentucky, Estados Unidos, 40536
        • University of Kentucky/Markey Cancer Center
      • Louisville, Kentucky, Estados Unidos, 40202
        • Norton Children's Hospital
    • Louisiana
      • New Orleans, Louisiana, Estados Unidos, 70118
        • Children's Hospital New Orleans
    • Maine
      • Bangor, Maine, Estados Unidos, 04401
        • Eastern Maine Medical Center
      • Brewer, Maine, Estados Unidos, 04412
        • Lafayette Family Cancer Center-EMMC
    • Maryland
      • Baltimore, Maryland, Estados Unidos, 21287
        • Johns Hopkins University/Sidney Kimmel Cancer Center
      • Baltimore, Maryland, Estados Unidos, 21215
        • Sinai Hospital of Baltimore
      • Bethesda, Maryland, Estados Unidos, 20892
        • National Institutes of Health Clinical Center
    • Massachusetts
      • Boston, Massachusetts, Estados Unidos, 02215
        • Dana-Farber Cancer Institute
      • Boston, Massachusetts, Estados Unidos, 02114
        • Massachusetts General Hospital Cancer Center
    • Michigan
      • Ann Arbor, Michigan, Estados Unidos, 48109
        • C S Mott Children's Hospital
      • Detroit, Michigan, Estados Unidos, 48201
        • Wayne State University/Karmanos Cancer Institute
      • Detroit, Michigan, Estados Unidos, 48236
        • Henry Ford Health Saint John Hospital
      • Port Huron, Michigan, Estados Unidos, 48060
        • Huron Medical Center PC
      • Royal Oak, Michigan, Estados Unidos, 48073
        • Corewell Health Children's
    • Minnesota
      • Minneapolis, Minnesota, Estados Unidos, 55404
        • Children's Hospitals and Clinics of Minnesota - Minneapolis
      • Minneapolis, Minnesota, Estados Unidos, 55455
        • University of Minnesota/Masonic Cancer Center
      • Rochester, Minnesota, Estados Unidos, 55905
        • Mayo Clinic in Rochester
    • Mississippi
      • Jackson, Mississippi, Estados Unidos, 39216
        • University of Mississippi Medical Center
    • Missouri
      • City of Saint Peters, Missouri, Estados Unidos, 63376
        • Siteman Cancer Center at Saint Peters Hospital
      • Creve Coeur, Missouri, Estados Unidos, 63141
        • Siteman Cancer Center at West County Hospital
      • Kansas City, Missouri, Estados Unidos, 64108
        • Children's Mercy Hospitals and Clinics
      • St Louis, Missouri, Estados Unidos, 63110
        • Barnes-Jewish Hospital
      • St Louis, Missouri, Estados Unidos, 63110
        • Washington University School of Medicine
      • St Louis, Missouri, Estados Unidos, 63129
        • Siteman Cancer Center-South County
      • St Louis, Missouri, Estados Unidos, 63141
        • Mercy Hospital Saint Louis
      • St Louis, Missouri, Estados Unidos, 63104
        • Cardinal Glennon Children's Medical Center
    • Nebraska
      • Omaha, Nebraska, Estados Unidos, 68198
        • University of Nebraska Medical Center
      • Omaha, Nebraska, Estados Unidos, 68114
        • Children's Hospital and Medical Center of Omaha
    • Nevada
      • Henderson, Nevada, Estados Unidos, 89052
        • Comprehensive Cancer Centers of Nevada-Horizon Ridge
      • Las Vegas, Nevada, Estados Unidos, 89144
        • Summerlin Hospital Medical Center
      • Las Vegas, Nevada, Estados Unidos, 89109
        • Sunrise Hospital and Medical Center
      • Las Vegas, Nevada, Estados Unidos, 89135
        • Alliance for Childhood Diseases/Cure 4 the Kids Foundation
      • Pahrump, Nevada, Estados Unidos, 89048
        • Hope Cancer Care of Nevada-Pahrump
      • Reno, Nevada, Estados Unidos, 89509
        • Radiation Oncology Associates
    • New Hampshire
      • Lebanon, New Hampshire, Estados Unidos, 03756
        • Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center
    • New Jersey
      • Hackensack, New Jersey, Estados Unidos, 07601
        • Hackensack University Medical Center
      • Morristown, New Jersey, Estados Unidos, 07960
        • Morristown Medical Center
      • New Brunswick, New Jersey, Estados Unidos, 08903
        • Rutgers Cancer Institute of New Jersey-Robert Wood Johnson University Hospital
    • New York
      • Buffalo, New York, Estados Unidos, 14263
        • Roswell Park Cancer Institute
      • Mineola, New York, Estados Unidos, 11501
        • NYU Langone Hospital - Long Island
      • New Hyde Park, New York, Estados Unidos, 11040
        • The Steven and Alexandra Cohen Children's Medical Center of New York
      • New York, New York, Estados Unidos, 10032
        • NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center
      • New York, New York, Estados Unidos, 10016
        • Laura and Isaac Perlmutter Cancer Center at NYU Langone
      • Syracuse, New York, Estados Unidos, 13210
        • State University of New York Upstate Medical University
    • North Carolina
      • Chapel Hill, North Carolina, Estados Unidos, 27599
        • UNC Lineberger Comprehensive Cancer Center
      • Charlotte, North Carolina, Estados Unidos, 28203
        • Carolinas Medical Center/Levine Cancer Institute
      • Clinton, North Carolina, Estados Unidos, 28328
        • Southeastern Medical Oncology Center-Clinton
      • Durham, North Carolina, Estados Unidos, 27710
        • Duke University Medical Center
      • Goldsboro, North Carolina, Estados Unidos, 27534
        • Southeastern Medical Oncology Center-Goldsboro
      • Goldsboro, North Carolina, Estados Unidos, 27534
        • Wayne Memorial Hospital
      • Greenville, North Carolina, Estados Unidos, 27834
        • East Carolina University
      • Jacksonville, North Carolina, Estados Unidos, 28546
        • Southeastern Medical Oncology Center-Jacksonville
    • Ohio
      • Cincinnati, Ohio, Estados Unidos, 45229
        • Cincinnati Children's Hospital Medical Center
      • Cleveland, Ohio, Estados Unidos, 44109
        • MetroHealth Medical Center
      • Cleveland, Ohio, Estados Unidos, 44195
        • Cleveland Clinic Foundation
      • Cleveland, Ohio, Estados Unidos, 44106
        • Rainbow Babies and Childrens Hospital
      • Columbus, Ohio, Estados Unidos, 43205
        • Nationwide Children's Hospital
      • Dayton, Ohio, Estados Unidos, 45404
        • Dayton Children's Hospital
      • Sylvania, Ohio, Estados Unidos, 43560
        • ProMedica Flower Hospital
      • Toledo, Ohio, Estados Unidos, 43606
        • ProMedica Toledo Hospital/Russell J Ebeid Children's Hospital
    • Oklahoma
      • Oklahoma City, Oklahoma, Estados Unidos, 73104
        • University of Oklahoma Health Sciences Center
    • Oregon
      • Portland, Oregon, Estados Unidos, 97239
        • Oregon Health and Science University
    • Pennsylvania
      • Philadelphia, Pennsylvania, Estados Unidos, 19104
        • Children's Hospital of Philadelphia
      • Pittsburgh, Pennsylvania, Estados Unidos, 15224
        • Children's Hospital of Pittsburgh of UPMC
    • South Carolina
      • Charleston, South Carolina, Estados Unidos, 29425
        • Medical University of South Carolina
      • Greenville, South Carolina, Estados Unidos, 29607
        • Saint Francis Cancer Center
      • Greenville, South Carolina, Estados Unidos, 29601
        • Saint Francis Hospital
      • Greenville, South Carolina, Estados Unidos, 29605
        • BI-LO Charities Children's Cancer Center
    • Tennessee
      • Knoxville, Tennessee, Estados Unidos, 37916
        • East Tennessee Childrens Hospital
      • Memphis, Tennessee, Estados Unidos, 38105
        • Saint Jude Children's Research Hospital
      • Nashville, Tennessee, Estados Unidos, 37203
        • The Children's Hospital at TriStar Centennial
    • Texas
      • Dallas, Texas, Estados Unidos, 75390
        • UT Southwestern/Simmons Cancer Center-Dallas
      • Dallas, Texas, Estados Unidos, 75230
        • Medical City Dallas Hospital
      • El Paso, Texas, Estados Unidos, 79905
        • El Paso Children's Hospital
      • El Paso, Texas, Estados Unidos, 79905
        • Texas Tech University Health Sciences Center-El Paso
      • Houston, Texas, Estados Unidos, 77030
        • Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center
      • San Antonio, Texas, Estados Unidos, 78207
        • Children's Hospital of San Antonio
    • Vermont
      • Burlington, Vermont, Estados Unidos, 05405
        • University of Vermont and State Agricultural College
    • Virginia
      • Norfolk, Virginia, Estados Unidos, 23507
        • Children's Hospital of The King's Daughters
    • Washington
      • Seattle, Washington, Estados Unidos, 98105
        • Seattle Children's Hospital
      • Spokane, Washington, Estados Unidos, 99204
        • Providence Sacred Heart Medical Center and Children's Hospital
    • Wisconsin
      • La Crosse, Wisconsin, Estados Unidos, 54601
        • Gundersen Lutheran Medical Center
      • Madison, Wisconsin, Estados Unidos, 53792
        • University of Wisconsin Carbone Cancer Center - University Hospital
      • Milwaukee, Wisconsin, Estados Unidos, 53226
        • Children's Hospital of Wisconsin

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

2 anos a 30 anos (Filho, Adulto)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Descrição

Inclusion Criteria:

  • Upper age limit of =< 18 years of age for medullary thyroid carcinoma (MTC), renal cell carcinoma (RCC) and hepatocellular carcinoma (HCC) =< 30 years for all other diagnoses

  • Patients must have a body surface area >= 0.35 m^2

  • Patients must have recurrent or refractory disease, or newly diagnosed disease with no known curative therapy or therapy proven to prolong survival with an acceptable quality of life; patients must have had histologic verification of one of the malignancies listed below at original diagnosis or at relapse:

    • Ewing sarcoma

    • Rhabdomyosarcoma (RMS)

    • Non-rhabdomyosarcoma soft tissue sarcomas (STS) including microphthalmia transcription factor associated STS (alveolar soft part sarcoma [ASPS] and clear cell sarcoma [CCS])

    • Osteosarcoma

    • Wilms tumor

    • Rare tumors

      • Medullary thyroid carcinoma (MTC)

      • Renal cell carcinoma (RCC)

      • Hepatocellular carcinoma (HCC)

      • Hepatoblastoma

      • Adrenal coertex carcinoma

      • Pediatric solid tumors (including central nervous system [CNS] tumors) with known molecular alterations in the targets of XL184 (i.e., MET amplification, overexpression, activating mutation, MET translocation, MET exon skipping mutations, activating RET mutations, RET rearrangement, overexpression or activation of AXL); documentation of the alteration from a Clinical Laboratory Improvement Act (CLIA) certified laboratory will be required

        • Note: Documentation of any known tumor molecular alterations and RET mutation status for patients with MTC (germline) must be uploaded via the RAVE system
  • Patients must have radiographically measurable disease; measurable disease is defined as the presence of at least one lesion on magnetic resonance imaging (MRI) or computed tomography (CT) scan that can be accurately measured with the longest diameter a minimum of 10 mm in at least one dimension (CT scan slice thickness no greater than 5 mm)

    • Note: The following do NOT qualify as measurable disease:

      • Malignant fluid collections (e.g., ascites, pleural effusions)
      • Bone marrow infiltration
      • Lesions only detected by nuclear medicine studies (e.g., bone, gallium or positron emission tomography [PET] scans)
      • Elevated tumor markers in plasma or cerebrospinal fluid (CSF)
      • Previously radiated lesions that have not demonstrated clear progression post radiation
      • Leptomeningeal lesions that do not meet the measurement parameters noted above
  • Patients must have a Lansky or Karnofsky performance status score of >= 50, corresponding to Eastern Cooperative Oncology Group (ECOG) categories 0, 1 or 2; use Karnofsky for patients > 16 years of age and Lansky for patients =< 16 years of age; patients who are unable to walk because of paralysis, but who are up in a wheelchair, will be considered ambulatory for the purpose of assessing the performance score

  • Patients must have fully recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy prior to entering this study

  • Patients with solid tumors must not have received myelosuppressive chemotherapy within 3 weeks of enrollment onto this study (6 weeks if prior nitrosourea)

  • At least 7 days must have elapsed since the completion of therapy with a growth factor. At least 14 days must have elapsed after receiving pegfilgrastim

  • Anti-cancer agents not known to be myelosuppressive (e.g. not associated with reduced platelet or absolute neutrophil count [ANC] counts): >= 7 days after the last dose of agent

  • Antibodies: >= 21 days must have elapsed from infusion of last dose of antibody, and toxicity related to prior antibody therapy must be recovered to grade =< 1

  • >= 2 weeks must have elapsed since local palliative radiation therapy (XRT) (small port); >= 6 weeks must have elapsed since treatment with therapeutic doses of M-Iodobenzylguanidine (MIBG); >= 3 months must have elapsed if prior craniospinal XRT was received, if >= 50% of the pelvis was irradiated, or if total-body irradiation (TBI) was received; >= 6 weeks must have elapsed if other substantial bone marrow irradiation was given

    • Subjects should not have any clinically relevant ongoing complications from prior radiation therapy (i.e., radiation esophagitis or other inflammation of the viscera)
  • No evidence of active graft versus (vs.) host disease and >= 2 months must have elapsed since transplant

  • Not previously received XL184 or another MET/HGF inhibitor (tivantinib or crizotinib); there are no limits on number of prior therapeutic regimens; patients who have been treated with prior VEGF pathway, or RET inhibitors (except XL184) may be eligible

  • Peripheral absolute neutrophil count (ANC) >= 1000/uL for patients with solid tumors without bone marrow involvement

  • Platelet count >= 100,000/uL (transfusion independent, defined as not receiving platelet transfusions within a 7 day period prior to enrollment) for patients with solid tumors without bone marrow involvement

  • Hemoglobin >= 8.0 g/dL (may receive red blood cell [RBC] transfusions) for patients with solid tumors without bone marrow involvement

  • Peripheral absolute neutrophil count (ANC) >= 750/uL for patients with solid tumors and known bone marrow metastatic disease

  • Platelet count >= 50,000/uL for patients with solid tumors and known bone marrow metastatic disease

  • Hemoglobin >= 8.0 g/dL for patients with solid tumors and known bone marrow metastatic disease

  • Transfusions are permitted to meet both the platelet and hemoglobin criteria for patients with known bone marrow metastatic disease; patients must not be known to be refractory to red blood cell or platelet transfusions

  • Creatinine clearance or radioisotope glomerular filtration rate (GFR) >= 70 mL/min/1.73 m^2 or a serum creatinine based on age/gender as follows:

    • 2 to < 6 years of age

      • Male and female: 0.8 (maximum serum creatinine [mg/dL])
    • 6 to < 10 years of age

      • Male and female: 1 (maximum serum creatinine [mg/dL])
    • 10 to < 13 years of age

      • Male and female: 1.2 (maximum serum creatinine [mg/dL])
    • 13 to < 16 years of age

      • Male 1.5 (maximum serum creatinine [mg/dL])
      • Female: 1.4 (maximum serum creatinine [mg/dL])
    • >= 16 years of age

      • Male: 1.7 (maximum serum creatinine [mg/dL])
      • Female: 1.4 (maximum serum creatinine [mg/dL])
  • Urine protein: =< 30 mg/dl in urinalysis or =< 1+ on dipstick, unless quantitative protein is < 1000 mg in a 24 hour (h) urine sample

  • Total bilirubin =< 1.5 x upper limit of normal (ULN) for age

  • Serum glutamate pyruvate transaminase (SGPT) (alanine aminotransferase [ALT]) =< 135 U/L (3 x ULN) (for the purpose of this study, the ULN for SGPT is 45 U/L)

  • Serum albumin >= 2.8 g/dL

  • No history of congenital prolonged corrected QT (QTc) syndrome, New York Heart Association (NYHA) class III or IV congestive heart failure (CHF)

  • No clinically significant cardiac arrhythmias, stroke or myocardial infarction within 6 months prior to enrollment

  • QTc =< 480 msec; Note: Patients with grade 1 prolonged QTc (450- 480 msec) at the time of study enrollment should have correctable causes of prolonged QTc addressed if possible (i.e., electrolytes, medications)

  • Patients with a known seizure disorder who are receiving non-enzyme inducing anticonvulsants and have well-controlled seizures may be enrolled

  • CNS toxicity =< grade 2 with the exception of decreased tendon reflex (DTR); any grade of DTR is eligible

  • A blood pressure (BP) =< the 95th percentile for age, height, and gender for pediatric patients < 18 years old and =< 140/90 mmHg for patients >= 18 years old; patients should not be receiving medication for treatment of hypertension (except patients with Wilms tumor and RCC who may be eligible if on stable doses of no more than one anti-hypertensive medication with a baseline BP =< ULN for pediatric patients and =< 140/90 for adult patients); please note that 3 serial blood pressures should be obtained and averaged to determine baseline BP

  • International normalized ratio (INR) =< 1.5

  • Serum amylase =< 1.5 x ULN

  • Serum lipase =< 1.5 x ULN

Exclusion Criteria:

  • Pregnant or breast-feeding women will not be entered on this study due to risks of fetal and teratogenic adverse events as seen in animal/human studies; pregnancy tests must be obtained in girls who are post-menarchal; males or females of reproductive potential may not participate unless they have agreed to use two methods of birth control- a medically accepted barrier method of contraceptive method (e.g., male or female condom) and a second effective method of birth control-during protocol therapy and for at least 4 months after the last dose of XL184; abstinence is an acceptable method of birth control

  • Growth factors that support platelet or white cell number or function must not have been administered within the 7 days prior to enrollment (14 days if pegfilgrastim)

  • Patients requiring corticosteroids who have not been on a stable or decreasing dose of corticosteroid for the 7 days prior to enrollment are not eligible; if used to modify immune adverse events related to prior therapy, >= 14 days must have elapsed since last dose of corticosteroid

  • Previous treatment with XL184 (cabozantinib) or another MET/HGF inhibitor (tivantinib, crizotinib)

  • Patients who are currently receiving another investigational drug are not eligible

  • Patients who are currently receiving other anti-cancer agents are not eligible

  • Patients who are receiving cyclosporine, tacrolimus or other agents to prevent either graft-versus-host disease post bone marrow transplant or organ rejection post-transplant are not eligible for this trial

  • Patients must not be receiving any of the following potent CYP3A4 inducers or inhibitors: erythromycin, clarithromycin, ketoconazole, azithromycin, itraconazole, grapefruit juice or St. John's wort

  • Concomitant anticoagulation with oral anticoagulants (e.g., warfarin, direct thrombin, and Factor Xa inhibitors) or platelet inhibitors (e.g., clopidogrel) are prohibited

    • Note: Low-dose aspirin for cardioprotection (per local applicable guidelines) and low dose, low molecular weight heparins (LMWH) are permitted; anticoagulation with therapeutic doses of LMWH is allowed in subjects without radiographic evidence of brain metastasis, who are on a stable dose of LMWH for at least 6 weeks before first dose of study treatment, and who have had no complications from a thromboembolic event or the anticoagulation regimen
  • Patients must not have received enzyme-inducing anticonvulsants within 14 days prior to enrollment

  • Patients who are receiving drugs that prolong QTc are not eligible

  • Patients who are unable to swallow intact tablets are not eligible

  • Patients who have an uncontrolled infection are not eligible

  • Patients who in the opinion of the investigator may not be able to comply with the safety monitoring requirements of the study are not eligible

  • Patients with active bleeding are not eligible; specifically, no clinically significant gastrointestinal (GI) bleeding, GI perforation, intra-abdominal abscess or fistula for 6 months prior to enrollment, no hemoptysis or other signs of pulmonary hemorrhage for 3 months prior to enrollment; patients with evidence of an acute intracranial or intratumoral hemorrhage on CT or MRI are not eligible (patients with evidence of resolving hemorrhage will be eligible); in patients with CNS tumors, an MRI with ECHO gradient sequences would be required to exclude presence of petechial hemorrhages

  • Patients who have had or are planning to have the following invasive procedures are not eligible:

    • Major surgical procedure, laparoscopic procedure, or open biopsy within 28 days prior to enrollment
    • Central line placement or subcutaneous port placement is not considered major surgery but must be placed at least 3 days prior to enrollment for external lines (e.g., Hickman or Broviac catheter, peripherally inserted central catheter [PICC]) and at least 7 days prior to enrollment for a subcutaneous port
    • Core biopsy within 7 days prior to enrollment
    • Fine needle aspirate within 7 days prior to enrollment
    • Surgical or other wounds must be adequately healed prior to enrollment
    • NOTE: For purposes of this study, bone marrow aspirate and biopsy are not considered surgical procedures and therefore are permitted within 14 days prior to start of protocol therapy
  • Patients who have had significant traumatic injury within 28 days prior to enrollment are not eligible

  • Patients with any medical or surgical conditions that would interfere with gastrointestinal absorption of the study drug are not eligible

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Tratamento
  • Alocação: N / D
  • Modelo Intervencional: Atribuição de grupo único
  • Mascaramento: Nenhum (rótulo aberto)

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: Treatment (cabozantinib s-malate)

Patients receive cabozantinib-s-malate orally (PO) on a continuous dosing schedule using a dosing nomogram on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.

Correlative studies

Given PO

Given PO

Note: Capsule formulation (Cometriq) not used in this trial.

Outros nomes:
  • BMS-907351
  • Cabometyx
  • Cometriq
  • XL-184
  • XL184
  • GG 184

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Objective Response (Non-Osteosarcoma Strata)
Prazo: Up to the first 6 cycles of therapy

Will be assessed by Response Evaluation Criteria in Solid Tumors version 1.1. Response rates will be calculated as the percent of evaluable patients who are responders (Overall Best Response of Partial Response or Complete Response), and confidence intervals will be constructed accounting for the two-stage design.

Up to the first 6 cycles of therapy
Objective Response (Osteosarcoma Stratum)
Prazo: Up to the first 6 cycles of therapy.

Will be assessed by the Response Evaluation Criteria in Solid Tumors version 1.1 and Disease Control (see section 9.3.2 of the ADVL1622 Protocol). Response + Disease Control rate will be calculated as the percent of evaluable patients who are responders or who met the definition of disease control, and confidence intervals will be constructed accounting for the two-stage design.

Up to the first 6 cycles of therapy.

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Percentage of Participants With Adverse Events
Prazo: Up to 5 years (duration of protocol therapy plus 30 days after last dose of therapy)

Will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0. Will report the percentage of patients within each disease stratum who experienced a grade 3 or higher toxicity with attribution of possible, probable, or definite while on protocol therapy or within 30 days of the last dose of therapy

Up to 5 years (duration of protocol therapy plus 30 days after last dose of therapy)
Pharmacokinetics (PK) Parameters of Cabozantinib S-malate: Cmax
Prazo: Prior to dose, 2, 4, 8 and 20-28 hours after dose on day 1

Day 1 PK peak concentration will be summarized by the mean and the standard deviation.

Prior to dose, 2, 4, 8 and 20-28 hours after dose on day 1
Pharmacokinetics (PK) Parameters of Cabozantinib S-malate: Tmax
Prazo: Prior to dose, 2, 4, 8 and 20-28 hours after dose on day 1

Day 1 PK time to peak concentration will be summarized by the mean and the standard deviation.

Prior to dose, 2, 4, 8 and 20-28 hours after dose on day 1
Pharmacokinetics (PK) Parameters of Cabozantinib S-malate: AUC
Prazo: Prior to dose, 2, 4, 8 and 20-28 hours after dose on day 1

Day 1 PK area under the curve will be summarized by the mean and the standard deviation.

Prior to dose, 2, 4, 8 and 20-28 hours after dose on day 1
Pharmacokinetics (PK) Parameters of Cabozantinib S-malate: Accumulation
Prazo: Cycle 1, Day 1 (20-28 hours after dose) and Cycle 1, Day 22

PK accumulation will be summarized by the mean and the standard deviation.

Cycle 1, Day 1 (20-28 hours after dose) and Cycle 1, Day 22
Pharmacokinetics (PK) Parameters of Cabozantinib S-malate: Half-life
Prazo: Cycle 1, Day 1 (20-28 hours after dose) and Cycle 1, Day 22

PK half-life will be summarized by the mean and the standard deviation.

Cycle 1, Day 1 (20-28 hours after dose) and Cycle 1, Day 22
Time to Progression (TTP)
Prazo: Up to 1 year

Percent of patients not yet progressed at 1 year as estimated by the Kaplan-Meier method. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECISTv1.1), as a >=20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions. Clinical progression was also counted as an event for this analysis.

Up to 1 year
Progression Free Survival (PFS)
Prazo: Up to 1 year

The 1-year Progression Free Survival will be estimated using Kaplan-Meier methodology. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECISTv1.1), as a >=20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions

Up to 1 year
Overall Survival (OS)
Prazo: Up to 1 year

The 1-year Overall Survival will be estimated using Kaplan-Meier methodology.

Up to 1 year

Outras medidas de resultado

Medida de resultado
Descrição da medida
Prazo
Change in Immune Biomarkers
Prazo: Baseline, day 1 (prior to dose) of cycles 2 and 3

The association between the host immune system and response to cabozantinib-s-malate will be assessed in an exploratory manner. each biomarker will be correlated with the clinical outcomes of objective response and progression free survival.

Baseline, day 1 (prior to dose) of cycles 2 and 3

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Patrocinador

Investigadores

  • Investigador principal: Srivandana Akshintala, Children's Oncology Group

Publicações e links úteis

A pessoa responsável por inserir informações sobre o estudo fornece voluntariamente essas publicações. Estes podem ser sobre qualquer coisa relacionada ao estudo.

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

18 de maio de 2017

Conclusão Primária (Real)

30 de junho de 2021

Conclusão do estudo (Estimado)

28 de junho de 2027

Datas de inscrição no estudo

Enviado pela primeira vez

15 de agosto de 2016

Enviado pela primeira vez que atendeu aos critérios de CQ

15 de agosto de 2016

Primeira postagem (Estimado)

16 de agosto de 2016

Atualizações de registro de estudo

Última Atualização Postada (Real)

13 de novembro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

10 de novembro de 2026

Última verificação

1 de junho de 2026

Mais Informações

Termos relacionados a este estudo

Termos MeSH relevantes adicionais

Outros números de identificação do estudo

  • NCI-2016-01258
  • U10CA180886 (Concessão/Contrato do NIH dos EUA)
  • NCI-2016-01258 (Identificador de registro: CTRP (Clinical Trial Reporting Program))
  • ADVL1622 (Outro identificador: CTEP)
  • ADVL1622
  • ADVL1622 (Outro identificador: Children's Oncology Group)

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Sim

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .